Board of Directors resolved to approve the 2022Q2 consolidated financial report
· Issued by Foresee Pharmaceuticals Co., Ltd.
Close
Today's Information
Provided by: Foresee Pharmaceuticals Co., Ltd.
SEQ_NO
1
Date of announcement
2022/08/08
Time of announcement
16:55:09
Subject
Foresee's Board of Directors resolved to approve
the 2022Q2 consolidated financial report
Date of events
2022/08/08
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved: 2022/08/08
2.Date of the audit committee approved: 2022/08/05
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD): 273,645
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD): 268,109
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD): (89,625)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD): (73,652)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD): (100,498)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD): (100,498)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD): (0.85)
11.Total assets end of the period (thousand NTD): 1,572,693
12.Total liabilities end of the period
(thousand NTD): 325,923
13.Equity attributable to owners of parent end of the
period (thousand NTD): 1,246,770
14.Any other matters that need to be specified: None
